

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/079453 A1

(51) International Patent Classification:

C07K 14/47 (2006.01) *A61P 27/02* (2006.01)
A61K 38/00 (2006.01) *C07K 16/22* (2006.01)
A61K 39/00 (2006.01) *C12N 15/86* (2006.01)
A61K 48/00 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2021/052689

(22) International Filing Date:

18 October 2021 (18.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2016463.8 16 October 2020 (16.10.2020) GB
2104148.8 24 March 2021 (24.03.2021) GB

(71) Applicant: **GYROSCOPE THERAPEUTICS LIMITED** [GB/GB]; 6th Floor, Rolling Stock Yard, 188 York Way, London N7 9AS (GB).

(72) Inventors: **JOEL, Josephine**; c/o Gyroscope Therapeutics Limited, 6th Floor, Rolling Stock Yard, 188 York Way, London N7 9AS (GB). **ESTEVE-RUDD, Julian**; c/o Gyroscope Therapeutics Limited, 6th Floor, Rolling Stock Yard, 188 York Way, London N7 9AS (GB). **TAM, Lawrence**; c/o Gyroscope Therapeutics Limited, 6th Floor, Rolling Stock Yard, 188 York Way, London N7 9AS (GB). **ELLIS, Scott**; c/o Gyroscope Therapeutics Limited, 6th Floor, Rolling Stock Yard, 188 York Way, London N7 9AS (GB).

(74) Agent: **D YOUNG & CO LLP**; 120 Holborn, London EC1N 2DY (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: NUCLEIC ACID ENCODING AN ANTI-VEGF ENTITY AND A NEGATIVE COMPLEMENT REGULATOR AND USES THEREOF FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION

(57) Abstract: The present invention relates to a product comprising (i) an anti- VEGF entity; and (ii) a negative complement regulator, or nucleotide sequences encoding therefor, as a combined preparation for simultaneous, separate or sequential use in therapy. In particular, the anti-VEGF entity is an anti-VEGF antibody, preferably aflibercept and the negative complement regulator is Complement Factor I (CFI) or Complement Factor H Like Protein 1 (FHL1). The main uses are for the treatment of eye diseases, in particular age-related macular degeneration (AMD).

WO 2022/079453 A1